← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Activesite Pharmaceuticals, Inc.
Berkeley, CA
$2,409,646
Total funding
2
Grants
Funding over time
peak $699.8K · FY2007–13$1M$750K$500K$250K$0
'07
'08
'09
'10
'11
'12
'13
Funding mix
By agency
NIH$2,409,646 · 2
By mechanism
R44$2,184,778 · 1
R43$224,868 · 1
Investigators at Activesite Pharmaceuticals, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Largest grants
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$699,825
R44 · FY2013 · EY
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$660,118
R44 · FY2012 · EY
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$435,382
R44 · FY2009 · EY
Novel Orally-Active Plasma Kallikrein Inhibitors for Diabetic Retinopathy$389,453
R44 · FY2010 · EY
Novel Anti-Thrombotic Approach for Treatment of Myocardial Infarction$224,868
R43 · FY2007 · HL